Management Change/Compensation (Form 8-K)

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Retirement of Chief Scientific Officer

On February 2, 2026, Khursheed Anwer informed Imunon, Inc. (the "Company") of his intent to retire as Executive Vice President and Chief Scientific Officer from the Company, and Dr. Anwer's employment with the Company will end, effective February 20, 2026 (the "Retirement Date"). Dr. Anwer's departure is without any disagreements with management. To help ensure a smooth transition of his responsibilities, Dr. Anwer and the Company agreed that he will transition to a consulting role with the Company.

On February 4, 2026, the Company and Dr. Anwer entered into a retirement and consulting agreement (the "Retirement and Consulting Agreement") pursuant to which he will provide the Company consulting services from his Retirement Date until December 31, 2026 (the "Consulting Period"). During the Consulting Period, Dr. Anwer will be paid a monthly retainer of $10,000. In addition, pursuant to the Retirement and Consulting Agreement, Dr. Anwer is entitled to receive (i) within 30 days following his Retirement Date, any accrued but unpaid salary and any unreimbursed business expenses incurred prior to his Retirement Date, (ii) continued payment of his base salary as severance pay for a period of twelve months following the Retirement Date and (iii) Company-paid COBRA coverage for a period of twelve months following the Retirement Date. The Retirement and Consulting Agreement is subject to a customary release of claims in the Company's favor.

The foregoing description of the Retirement and Consulting Agreement is not complete and is qualified in its entirety by reference to the Retirement and Consulting Agreement, which is filed herewith as Exhibit 10.1 and incorporated by reference herein.